netFormulary NHS
Milton Keynes Formulary
Milton Keynes University Hospital NHS Foundation Trust
Milton Keynes Clinical Commissioning Group
Milton Keynes Community Health Services
 Search
 Formulary Chapter 6: Endocrine system - Full Chapter
Chapter Links...
 Details...
06.06.02  Expand sub section  Bisphosphonates and other drugs affecting bone metabolism
06.06.02  Expand sub section  Bisphosphonates
Alendronic Acid
(Once-Weekly)
View adult BNF View SPC online View childrens BNF
Formulary
Green

Tablets 70mg

 
   
Alendronic Acid
(Once Daily)
View adult BNF View SPC online View childrens BNF
Formulary
Green

Tablets 10mg

 
   
Alendronic Acid effervescent (Binosto)
(Once-Weekly)
View adult BNF View SPC online View childrens BNF
Formulary
Amber 2

Tablets 70mg (Binosto)


Notes:
Reserved for patients who have confirmed swallowing difficulties
For hospital initiation only in line with local guideline after failure of standard
Alendronic acid and risedronate.

 
   
Clodronate Sodium
View adult BNF View SPC online View childrens BNF
Formulary
Amber 1

Tablets 520mg, 800mg

 
   
Pamidronate
View adult BNF View SPC online View childrens BNF
Formulary
Red

Injection 15mg, 30mg, 60mg, 90mg

 

IV disodium pamidronate is licensed to treat hypercalcaemia, osteolytic lesions
and bone pain linked to bone/skeletal metastases and that related to Paget’s
disease.

 
Link  MHRA: osteonecrosis of the jaw - risk minimisation (July 15)
   
Risedronate
View adult BNF View SPC online View childrens BNF
Formulary
Green

Tablets 5mg, 35mg

 
   
Zoledronic Acid
(5mg - Osteoporosis/Paget's)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Homecare

Injection 5mg/100mL solution for infusion in vial for patients unable to take
oral medication for post-menopausal osteoporosis.

Zometa® Concentrate for Intravenous Infusion 4mg/5mL for prophylaxis &
treatment of Osteolytic lesions and treatment of Hypercalcaemia &
Bone Metastases

 

 
Link  Osteonecrosis of the jaw patient reminder cards
Link  MHRA: osteonecrosis of the jaw - risk minimisation (July 15)
   
06.06.02  Expand sub section  Denosumab
06.06.02  Expand sub section  Strontium ranelate
 ....
 Non Formulary Items
Alendronic Acid with colecalciferol  (Fosavance)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Disodium Etidronate  (Didronel PMO)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Ibandronic Acid
(oncology)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Ibandronic Acid
(osteoporosis)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Ibandronic Acid injection  (Bonviva)

View adult BNF View SPC online View childrens BNF
Non Formulary
Link  MHRA: osteonecrosis of the jaw - risk minimisation (July 15)
 
Ibandronic acid IV infusion  (Bondronat)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Risedronate
(daily for Paget's)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Tiludronic Acid  (Skelid)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Zoledronic Acid  (4mg - hypercalcaemia/malignancy)

View adult BNF View SPC online View childrens BNF
Non Formulary
Link  Osteonecrosis of the jaw patient reminder cards
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Green

Routine prescribing within licensed indication  

Amber 1

Specialist recommendation followed by GP initiation and continuation  

Amber 2

Specialist or GP initiation in line with local guideline after 1st line failure followed by GP continuation   

Amber 3

Specialist initiation and stabilisation followed by GP continuation  

Amber SCG

Specialist initiation and stabilisation followed by GP continuation in line with an agreed shared care guideline  

Red

Hospital or specialist prescribing only  

Red Red

These medicines have been evaluated and rejected by MKPAG and are NOT approved for use within MK. They are not recommended for use because of lack of clinical effectiveness, cost effectiveness or safety.  

netFormulary